Physician profile
Curt E Coulter
NPI 1407958572
$15,142.91
in general payments reported to CMS, 2019-2025
53 companies · $2,690 in 2025
The $2,690 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,888 · 2020: $1,513 · 2021: $2,152 · 2022: $2,093 · 2023: $2,435 · 2024: $2,372 · 2025: $2,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,398 · Education: $98.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,398.27 |
| Education | $98.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,858.10 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $1,365.75 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Novo Nordisk INC | $1,212.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,187.71 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,039.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $882.53 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $877.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $744.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $522.59 | 2019-2025 | Veozah, Myrbetriq |
| Harmony Biosciences LLC | $490.58 | 2021-2025 | Wakix |
| Janssen Pharmaceuticals, INC | $415.62 | 2019-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.16 | 2019-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $376.13 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $361.27 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $349.19 | 2019-2023 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $298.03 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $253.29 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $212.37 | 2019-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $183.25 | 2022 | |
| Allergan, INC. | $167.47 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $153.93 | 2025 | Fanapt |
| Teleflex LLC | $146.94 | 2025 | Urolift |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.21 | 2023-2025 | Caplyta |
| Horizon Therapeutics Plc | $128.49 | 2019-2023 | Krystexxa |
| Amarin Pharma, INC. | $128.02 | 2020-2022 | |
| Abbott Laboratories | $92.47 | 2023-2025 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $85.68 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $81.30 | 2020-2024 | Yupelri |
| Esperion Therapeutics, INC. | $73.41 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $73.05 | 2019-2025 | Gattex, Trintellix, Eohilia |
| Biohaven Pharmaceuticals, INC. | $69.50 | 2021 | |
| Dexcom, INC. | $68.85 | 2021-2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $66.50 | 2022-2025 | Flucelvax, Fluad |
| Lundbeck LLC | $61.60 | 2022-2025 | Rexulti |
| Cardiovascular Systems INC. | $60.51 | 2021 | |
| Axsome Therapeutics, INC. | $58.26 | 2024-2025 | Auvelity |
| Alnylam Pharmaceuticals INC. | $50.58 | 2021-2023 | Givlaari |
| Corcept Therapeutics | $46.85 | 2025 | Korlym |
| Vertex Pharmaceuticals Incorporated | $42.86 | 2025 | |
| Eisai INC. | $42.04 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $41.58 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $36.67 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $34.10 | 2022-2023 | |
| Optinose US, INC. | $33.48 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.63 | 2019 | |
| Tactile Systems Technology INC | $22.04 | 2025 | Flexitouch Plus, Nimbl |
| Ucb, INC. | $19.19 | 2024 | Nayzilam |
| Impel Pharmaceuticals INC. | $16.98 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.91 | 2023 | Strensiq |
| Pulmonx Corporation | $16.16 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Currax Pharmaceuticals LLC | $13.94 | 2020 | |
| Indivior INC. | $13.28 | 2024 | Sublocade |
| Mayne Pharma Commercial LLC | $5.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curt Coulter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.